US8658139B1 - Prevention and treatment of oral diseases - Google Patents
Prevention and treatment of oral diseases Download PDFInfo
- Publication number
- US8658139B1 US8658139B1 US12/660,485 US66048510A US8658139B1 US 8658139 B1 US8658139 B1 US 8658139B1 US 66048510 A US66048510 A US 66048510A US 8658139 B1 US8658139 B1 US 8658139B1
- Authority
- US
- United States
- Prior art keywords
- weight
- dental
- oral
- mouth
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active, expires
Links
- 238000011282 treatment Methods 0.000 title abstract description 7
- 230000002265 prevention Effects 0.000 title abstract description 6
- 208000025157 Oral disease Diseases 0.000 title description 2
- 208000030194 mouth disease Diseases 0.000 title description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims abstract description 49
- 208000002925 dental caries Diseases 0.000 claims abstract description 32
- 206010013781 dry mouth Diseases 0.000 claims abstract description 29
- 239000004615 ingredient Substances 0.000 claims abstract description 29
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims abstract description 28
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims abstract description 28
- 239000000811 xylitol Substances 0.000 claims abstract description 28
- 235000010447 xylitol Nutrition 0.000 claims abstract description 28
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims abstract description 28
- 229960002675 xylitol Drugs 0.000 claims abstract description 28
- 239000004094 surface-active agent Substances 0.000 claims abstract description 23
- 206010020751 Hypersensitivity Diseases 0.000 claims abstract description 22
- 208000026935 allergic disease Diseases 0.000 claims abstract description 22
- 230000009610 hypersensitivity Effects 0.000 claims abstract description 22
- 229910000019 calcium carbonate Inorganic materials 0.000 claims abstract description 21
- 239000002245 particle Substances 0.000 claims abstract description 21
- 238000000034 method Methods 0.000 claims abstract description 19
- 208000007027 Oral Candidiasis Diseases 0.000 claims abstract description 16
- 206010006326 Breath odour Diseases 0.000 claims abstract description 15
- 208000006558 Dental Calculus Diseases 0.000 claims abstract description 15
- 208000032139 Halitosis Diseases 0.000 claims abstract description 15
- 208000005946 Xerostomia Diseases 0.000 claims abstract description 14
- 208000028169 periodontal disease Diseases 0.000 claims abstract description 12
- 208000004898 Herpes Labialis Diseases 0.000 claims abstract description 10
- 206010067152 Oral herpes Diseases 0.000 claims abstract description 10
- 208000002399 aphthous stomatitis Diseases 0.000 claims abstract description 10
- 208000003265 stomatitis Diseases 0.000 claims abstract description 9
- 206010049047 Chapped lips Diseases 0.000 claims abstract description 8
- 201000004624 Dermatitis Diseases 0.000 claims abstract description 8
- 208000009675 Perioral Dermatitis Diseases 0.000 claims abstract description 8
- 239000000606 toothpaste Substances 0.000 claims description 40
- 229940034610 toothpaste Drugs 0.000 claims description 35
- 239000006072 paste Substances 0.000 claims description 29
- 230000000622 irritating effect Effects 0.000 claims description 21
- 229920001983 poloxamer Polymers 0.000 claims description 21
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 19
- 239000000796 flavoring agent Substances 0.000 claims description 19
- 235000019634 flavors Nutrition 0.000 claims description 19
- 239000000551 dentifrice Substances 0.000 claims description 18
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 claims description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 14
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims description 13
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 12
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 12
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 12
- 210000003298 dental enamel Anatomy 0.000 claims description 12
- 239000008187 granular material Substances 0.000 claims description 12
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 235000010216 calcium carbonate Nutrition 0.000 claims description 11
- 238000011321 prophylaxis Methods 0.000 claims description 10
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 9
- 239000011575 calcium Substances 0.000 claims description 9
- 229910052791 calcium Inorganic materials 0.000 claims description 9
- 235000013305 food Nutrition 0.000 claims description 9
- -1 polydimethylsiloxanes Polymers 0.000 claims description 9
- 239000003826 tablet Substances 0.000 claims description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 8
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 8
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 8
- 229920002125 Sokalan® Polymers 0.000 claims description 8
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 8
- 229920001586 anionic polysaccharide Polymers 0.000 claims description 8
- 150000004836 anionic polysaccharides Chemical class 0.000 claims description 8
- 235000010980 cellulose Nutrition 0.000 claims description 8
- 229920002678 cellulose Polymers 0.000 claims description 8
- 239000002537 cosmetic Substances 0.000 claims description 8
- 201000002170 dentin sensitivity Diseases 0.000 claims description 8
- 239000003599 detergent Substances 0.000 claims description 8
- 239000007937 lozenge Substances 0.000 claims description 8
- 239000002324 mouth wash Substances 0.000 claims description 8
- 229940051866 mouthwash Drugs 0.000 claims description 8
- 229960000502 poloxamer Drugs 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 239000000377 silicon dioxide Substances 0.000 claims description 8
- 239000011775 sodium fluoride Substances 0.000 claims description 8
- 235000013024 sodium fluoride Nutrition 0.000 claims description 8
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 8
- 230000036347 tooth sensitivity Effects 0.000 claims description 8
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 7
- 229940112822 chewing gum Drugs 0.000 claims description 7
- 235000015218 chewing gum Nutrition 0.000 claims description 7
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 6
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 208000024693 gingival disease Diseases 0.000 claims description 6
- 235000011187 glycerol Nutrition 0.000 claims description 6
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 6
- 229910052751 metal Inorganic materials 0.000 claims description 6
- 239000002184 metal Substances 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 239000002562 thickening agent Substances 0.000 claims description 6
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 claims description 5
- 102000010445 Lactoferrin Human genes 0.000 claims description 5
- 108010063045 Lactoferrin Proteins 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 229940091249 fluoride supplement Drugs 0.000 claims description 5
- 230000037406 food intake Effects 0.000 claims description 5
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims description 5
- 229940078795 lactoferrin Drugs 0.000 claims description 5
- 235000021242 lactoferrin Nutrition 0.000 claims description 5
- 241000894006 Bacteria Species 0.000 claims description 4
- BCZXFFBUYPCTSJ-UHFFFAOYSA-L Calcium propionate Chemical compound [Ca+2].CCC([O-])=O.CCC([O-])=O BCZXFFBUYPCTSJ-UHFFFAOYSA-L 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- INVGWHRKADIJHF-UHFFFAOYSA-N Sanguinarin Chemical compound C1=C2OCOC2=CC2=C3[N+](C)=CC4=C(OCO5)C5=CC=C4C3=CC=C21 INVGWHRKADIJHF-UHFFFAOYSA-N 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- 150000007513 acids Chemical class 0.000 claims description 4
- 235000013334 alcoholic beverage Nutrition 0.000 claims description 4
- 235000010323 ascorbic acid Nutrition 0.000 claims description 4
- 239000011668 ascorbic acid Substances 0.000 claims description 4
- 229960005070 ascorbic acid Drugs 0.000 claims description 4
- 235000010331 calcium propionate Nutrition 0.000 claims description 4
- 239000004330 calcium propionate Substances 0.000 claims description 4
- 229920003086 cellulose ether Polymers 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 4
- 244000052769 pathogen Species 0.000 claims description 4
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 239000003755 preservative agent Substances 0.000 claims description 4
- 230000002335 preservative effect Effects 0.000 claims description 4
- 235000000346 sugar Nutrition 0.000 claims description 4
- 150000008163 sugars Chemical class 0.000 claims description 4
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 claims description 4
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 4
- XGRSAFKZAGGXJV-UHFFFAOYSA-N 3-azaniumyl-3-cyclohexylpropanoate Chemical compound OC(=O)CC(N)C1CCCCC1 XGRSAFKZAGGXJV-UHFFFAOYSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- 239000004378 Glycyrrhizin Substances 0.000 claims description 3
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 claims description 3
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 claims description 3
- 239000004599 antimicrobial Substances 0.000 claims description 3
- 230000001680 brushing effect Effects 0.000 claims description 3
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 3
- 229960001927 cetylpyridinium chloride Drugs 0.000 claims description 3
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 claims description 3
- MRUAUOIMASANKQ-UHFFFAOYSA-N cocamidopropyl betaine Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC([O-])=O MRUAUOIMASANKQ-UHFFFAOYSA-N 0.000 claims description 3
- 229940073507 cocamidopropyl betaine Drugs 0.000 claims description 3
- 239000006260 foam Substances 0.000 claims description 3
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims description 3
- 229960004949 glycyrrhizic acid Drugs 0.000 claims description 3
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims description 3
- 235000019410 glycyrrhizin Nutrition 0.000 claims description 3
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 3
- 239000003906 humectant Substances 0.000 claims description 3
- 239000000314 lubricant Substances 0.000 claims description 3
- 150000002739 metals Chemical class 0.000 claims description 3
- 229920005862 polyol Polymers 0.000 claims description 3
- 150000003077 polyols Chemical class 0.000 claims description 3
- 108700004121 sarkosyl Proteins 0.000 claims description 3
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 claims description 3
- 229960004711 sodium monofluorophosphate Drugs 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- 235000010356 sorbitol Nutrition 0.000 claims description 3
- 229960003500 triclosan Drugs 0.000 claims description 3
- 229920001285 xanthan gum Polymers 0.000 claims description 3
- 235000010493 xanthan gum Nutrition 0.000 claims description 3
- 239000000230 xanthan gum Substances 0.000 claims description 3
- 229940082509 xanthan gum Drugs 0.000 claims description 3
- WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 claims description 2
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 2
- 244000215068 Acacia senegal Species 0.000 claims description 2
- 108010011485 Aspartame Proteins 0.000 claims description 2
- 241000416162 Astragalus gummifer Species 0.000 claims description 2
- 206010007134 Candida infections Diseases 0.000 claims description 2
- 229920001412 Chicle Polymers 0.000 claims description 2
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 claims description 2
- 244000223760 Cinnamomum zeylanicum Species 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 2
- 239000004386 Erythritol Substances 0.000 claims description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 2
- FCEXWTOTHXCQCQ-UHFFFAOYSA-N Ethoxydihydrosanguinarine Natural products C12=CC=C3OCOC3=C2C(OCC)N(C)C(C2=C3)=C1C=CC2=CC1=C3OCO1 FCEXWTOTHXCQCQ-UHFFFAOYSA-N 0.000 claims description 2
- 239000001856 Ethyl cellulose Substances 0.000 claims description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 2
- WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 claims description 2
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 2
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 2
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 2
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 2
- 229920000084 Gum arabic Polymers 0.000 claims description 2
- 229920000569 Gum karaya Polymers 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- 240000001794 Manilkara zapota Species 0.000 claims description 2
- 235000011339 Manilkara zapota Nutrition 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 claims description 2
- 244000024873 Mentha crispa Species 0.000 claims description 2
- 235000014749 Mentha crispa Nutrition 0.000 claims description 2
- 108010014251 Muramidase Proteins 0.000 claims description 2
- 102000016943 Muramidase Human genes 0.000 claims description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 2
- 229920000388 Polyphosphate Polymers 0.000 claims description 2
- 241000934878 Sterculia Species 0.000 claims description 2
- 244000228451 Stevia rebaudiana Species 0.000 claims description 2
- 239000004376 Sucralose Substances 0.000 claims description 2
- 235000016639 Syzygium aromaticum Nutrition 0.000 claims description 2
- 244000223014 Syzygium aromaticum Species 0.000 claims description 2
- 102000006463 Talin Human genes 0.000 claims description 2
- 108010083809 Talin Proteins 0.000 claims description 2
- 239000005844 Thymol Substances 0.000 claims description 2
- 229920001615 Tragacanth Polymers 0.000 claims description 2
- 241000287411 Turdidae Species 0.000 claims description 2
- 235000010489 acacia gum Nutrition 0.000 claims description 2
- 239000000205 acacia gum Substances 0.000 claims description 2
- YGCFIWIQZPHFLU-UHFFFAOYSA-N acesulfame Chemical compound CC1=CC(=O)NS(=O)(=O)O1 YGCFIWIQZPHFLU-UHFFFAOYSA-N 0.000 claims description 2
- 229960005164 acesulfame Drugs 0.000 claims description 2
- 229950010221 alexidine Drugs 0.000 claims description 2
- LFVVNPBBFUSSHL-UHFFFAOYSA-N alexidine Chemical compound CCCCC(CC)CNC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NCC(CC)CCCC LFVVNPBBFUSSHL-UHFFFAOYSA-N 0.000 claims description 2
- 235000010443 alginic acid Nutrition 0.000 claims description 2
- 239000000783 alginic acid Substances 0.000 claims description 2
- 229920000615 alginic acid Polymers 0.000 claims description 2
- 229960001126 alginic acid Drugs 0.000 claims description 2
- 150000004781 alginic acids Chemical class 0.000 claims description 2
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims description 2
- 229940087168 alpha tocopherol Drugs 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 230000003078 antioxidant effect Effects 0.000 claims description 2
- 235000006708 antioxidants Nutrition 0.000 claims description 2
- 239000000605 aspartame Substances 0.000 claims description 2
- 235000010357 aspartame Nutrition 0.000 claims description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 2
- 229960003438 aspartame Drugs 0.000 claims description 2
- 235000013871 bee wax Nutrition 0.000 claims description 2
- 239000012166 beeswax Substances 0.000 claims description 2
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 2
- 229960001950 benzethonium chloride Drugs 0.000 claims description 2
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 claims description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 2
- 235000013734 beta-carotene Nutrition 0.000 claims description 2
- 239000011648 beta-carotene Substances 0.000 claims description 2
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims description 2
- 229960002747 betacarotene Drugs 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- JUNWLZAGQLJVLR-UHFFFAOYSA-J calcium diphosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O JUNWLZAGQLJVLR-UHFFFAOYSA-J 0.000 claims description 2
- 229940043256 calcium pyrophosphate Drugs 0.000 claims description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims description 2
- 235000013539 calcium stearate Nutrition 0.000 claims description 2
- 239000008116 calcium stearate Substances 0.000 claims description 2
- 201000003984 candidiasis Diseases 0.000 claims description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 2
- 229940105329 carboxymethylcellulose Drugs 0.000 claims description 2
- 235000010418 carrageenan Nutrition 0.000 claims description 2
- 239000000679 carrageenan Substances 0.000 claims description 2
- 229920001525 carrageenan Polymers 0.000 claims description 2
- 229940113118 carrageenan Drugs 0.000 claims description 2
- RECUKUPTGUEGMW-UHFFFAOYSA-N carvacrol Chemical compound CC(C)C1=CC=C(C)C(O)=C1 RECUKUPTGUEGMW-UHFFFAOYSA-N 0.000 claims description 2
- 235000007746 carvacrol Nutrition 0.000 claims description 2
- HHTWOMMSBMNRKP-UHFFFAOYSA-N carvacrol Natural products CC(=C)C1=CC=C(C)C(O)=C1 HHTWOMMSBMNRKP-UHFFFAOYSA-N 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 229960003260 chlorhexidine Drugs 0.000 claims description 2
- 229960005233 cineole Drugs 0.000 claims description 2
- 235000017803 cinnamon Nutrition 0.000 claims description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 235000009508 confectionery Nutrition 0.000 claims description 2
- 235000019821 dicalcium diphosphate Nutrition 0.000 claims description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 2
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 claims description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims description 2
- LRCFXGAMWKDGLA-UHFFFAOYSA-N dioxosilane;hydrate Chemical compound O.O=[Si]=O LRCFXGAMWKDGLA-UHFFFAOYSA-N 0.000 claims description 2
- 235000011180 diphosphates Nutrition 0.000 claims description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 2
- 235000019414 erythritol Nutrition 0.000 claims description 2
- 229940009714 erythritol Drugs 0.000 claims description 2
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 2
- 229920001249 ethyl cellulose Polymers 0.000 claims description 2
- 229910052587 fluorapatite Inorganic materials 0.000 claims description 2
- 238000005187 foaming Methods 0.000 claims description 2
- 235000003599 food sweetener Nutrition 0.000 claims description 2
- 229960005150 glycerol Drugs 0.000 claims description 2
- 230000005802 health problem Effects 0.000 claims description 2
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 2
- 229910052816 inorganic phosphate Inorganic materials 0.000 claims description 2
- WYXXLXHHWYNKJF-UHFFFAOYSA-N isocarvacrol Natural products CC(C)C1=CC=C(O)C(C)=C1 WYXXLXHHWYNKJF-UHFFFAOYSA-N 0.000 claims description 2
- 235000010494 karaya gum Nutrition 0.000 claims description 2
- 239000000231 karaya gum Substances 0.000 claims description 2
- 229940039371 karaya gum Drugs 0.000 claims description 2
- 229940010454 licorice Drugs 0.000 claims description 2
- 239000004325 lysozyme Substances 0.000 claims description 2
- 235000010335 lysozyme Nutrition 0.000 claims description 2
- 229960000274 lysozyme Drugs 0.000 claims description 2
- 235000019359 magnesium stearate Nutrition 0.000 claims description 2
- 235000010449 maltitol Nutrition 0.000 claims description 2
- 239000000845 maltitol Substances 0.000 claims description 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims description 2
- 229940035436 maltitol Drugs 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 229960001855 mannitol Drugs 0.000 claims description 2
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 claims description 2
- 229960003987 melatonin Drugs 0.000 claims description 2
- 125000005341 metaphosphate group Chemical group 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 235000010981 methylcellulose Nutrition 0.000 claims description 2
- 235000010987 pectin Nutrition 0.000 claims description 2
- 239000001814 pectin Substances 0.000 claims description 2
- 229920001277 pectin Polymers 0.000 claims description 2
- 229960000292 pectin Drugs 0.000 claims description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 2
- 229920000058 polyacrylate Polymers 0.000 claims description 2
- 229920001083 polybutene Polymers 0.000 claims description 2
- 239000001205 polyphosphate Substances 0.000 claims description 2
- 235000011176 polyphosphates Nutrition 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 239000004302 potassium sorbate Substances 0.000 claims description 2
- 235000010241 potassium sorbate Nutrition 0.000 claims description 2
- 229940069338 potassium sorbate Drugs 0.000 claims description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 claims description 2
- 235000019204 saccharin Nutrition 0.000 claims description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 claims description 2
- 229940081974 saccharin Drugs 0.000 claims description 2
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 claims description 2
- 229940084560 sanguinarine Drugs 0.000 claims description 2
- YZRQUTZNTDAYPJ-UHFFFAOYSA-N sanguinarine pseudobase Natural products C1=C2OCOC2=CC2=C3N(C)C(O)C4=C(OCO5)C5=CC=C4C3=CC=C21 YZRQUTZNTDAYPJ-UHFFFAOYSA-N 0.000 claims description 2
- 229960004029 silicic acid Drugs 0.000 claims description 2
- 229940048109 sodium methyl cocoyl taurate Drugs 0.000 claims description 2
- IWIUXJGIDSGWDN-UQKRIMTDSA-M sodium;(2s)-2-(dodecanoylamino)pentanedioate;hydron Chemical compound [Na+].CCCCCCCCCCCC(=O)N[C@H](C([O-])=O)CCC(O)=O IWIUXJGIDSGWDN-UQKRIMTDSA-M 0.000 claims description 2
- 229960002920 sorbitol Drugs 0.000 claims description 2
- 235000019408 sucralose Nutrition 0.000 claims description 2
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 2
- 239000003765 sweetening agent Substances 0.000 claims description 2
- 235000010436 thaumatin Nutrition 0.000 claims description 2
- 229960000790 thymol Drugs 0.000 claims description 2
- 229960000984 tocofersolan Drugs 0.000 claims description 2
- 235000019731 tricalcium phosphate Nutrition 0.000 claims description 2
- 239000000341 volatile oil Substances 0.000 claims description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 2
- 239000002076 α-tocopherol Substances 0.000 claims description 2
- 235000004835 α-tocopherol Nutrition 0.000 claims description 2
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims description 2
- 229940023487 dental product Drugs 0.000 claims 20
- 230000007423 decrease Effects 0.000 claims 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 claims 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 claims 1
- 229920001400 block copolymer Polymers 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 239000003921 oil Substances 0.000 claims 1
- 235000019198 oils Nutrition 0.000 claims 1
- 230000009747 swallowing Effects 0.000 claims 1
- 239000002085 irritant Substances 0.000 abstract description 5
- 231100000021 irritant Toxicity 0.000 abstract description 5
- 239000000047 product Substances 0.000 description 57
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 20
- 210000005239 tubule Anatomy 0.000 description 18
- 230000000694 effects Effects 0.000 description 9
- 229910021532 Calcite Inorganic materials 0.000 description 8
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 8
- 229920003095 Methocel™ K15M Polymers 0.000 description 7
- 239000001506 calcium phosphate Substances 0.000 description 7
- 229910000389 calcium phosphate Inorganic materials 0.000 description 7
- 235000011010 calcium phosphates Nutrition 0.000 description 7
- 229920001992 poloxamer 407 Polymers 0.000 description 7
- 239000002105 nanoparticle Substances 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- ANOBYBYXJXCGBS-UHFFFAOYSA-L stannous fluoride Chemical compound F[Sn]F ANOBYBYXJXCGBS-UHFFFAOYSA-L 0.000 description 5
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 4
- 150000001450 anions Chemical class 0.000 description 4
- 230000007794 irritation Effects 0.000 description 4
- 210000004872 soft tissue Anatomy 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000002882 anti-plaque Effects 0.000 description 3
- 159000000007 calcium salts Chemical class 0.000 description 3
- 239000000084 colloidal system Substances 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 229920000620 organic polymer Polymers 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 2
- 108010001682 Dextranase Proteins 0.000 description 2
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 2
- 208000012868 Overgrowth Diseases 0.000 description 2
- 241000282320 Panthera leo Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 239000000378 calcium silicate Substances 0.000 description 2
- 229910052918 calcium silicate Inorganic materials 0.000 description 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000003975 dentin desensitizing agent Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 235000010333 potassium nitrate Nutrition 0.000 description 2
- 239000004323 potassium nitrate Substances 0.000 description 2
- 159000000001 potassium salts Chemical class 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 229910001631 strontium chloride Inorganic materials 0.000 description 2
- AHBGXTDRMVNFER-UHFFFAOYSA-L strontium dichloride Chemical compound [Cl-].[Cl-].[Sr+2] AHBGXTDRMVNFER-UHFFFAOYSA-L 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- RYJDNPSQBGFFSF-WCCKRBBISA-N (2s)-2-amino-5-(diaminomethylideneamino)pentanoic acid;carbonic acid Chemical compound OC(O)=O.OC(=O)[C@@H](N)CCCNC(N)=N RYJDNPSQBGFFSF-WCCKRBBISA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 229920005682 EO-PO block copolymer Polymers 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 208000019025 Hypokalemia Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000007117 Oral Ulcer Diseases 0.000 description 1
- 108010001441 Phosphopeptides Proteins 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 241000519995 Stachys sylvatica Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- VEUACKUBDLVUAC-UHFFFAOYSA-N [Na].[Ca] Chemical compound [Na].[Ca] VEUACKUBDLVUAC-UHFFFAOYSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000002053 acidogenic effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000000675 anti-caries Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 206010006514 bruxism Diseases 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 239000003922 charged colloid Substances 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 235000021270 cold food Nutrition 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000000001 dental powder Substances 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000010304 firing Methods 0.000 description 1
- 235000007983 food acid Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 201000005562 gingival recession Diseases 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000021268 hot food Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- NESFGLPJMFXSTK-UHFFFAOYSA-N hypochlorous acid;propane-1,2-diol Chemical compound ClO.CC(O)CO NESFGLPJMFXSTK-UHFFFAOYSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940094522 laponite Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- XCOBTUNSZUJCDH-UHFFFAOYSA-B lithium magnesium sodium silicate Chemical compound [Li+].[Li+].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Na+].[Na+].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3 XCOBTUNSZUJCDH-UHFFFAOYSA-B 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 150000002736 metal compounds Chemical class 0.000 description 1
- 239000013081 microcrystal Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 239000002159 nanocrystal Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000005360 phosphosilicate glass Substances 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920005646 polycarboxylate Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 208000024896 potassium deficiency disease Diseases 0.000 description 1
- 230000000395 remineralizing effect Effects 0.000 description 1
- 235000021148 salty food Nutrition 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0216—Solid or semisolid forms
- A61K8/022—Powders; Compacted Powders
- A61K8/0225—Granulated powders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/731—Cellulose; Quaternized cellulose derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/90—Block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/001—Preparations for care of the lips
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/413—Nanosized, i.e. having sizes below 100 nm
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/594—Mixtures of polymers
Definitions
- This invention comprises a set of dental products and methods to prevent and treat dentinal hypersensitivity, prevent tooth decay, and heal incipient caries by means of Mouth Friendly® dental products containing calcium carbonate, having a preferred particle size of 1 to 100 nanometers (nm), and a preferred weight range of 5 to 30%.
- Said products must contain 8 to 95 weight percent of xylitol, plus the surfactant system described in U.S. Pat. No. 5,496,541 (Mar. 5, 1996) and U.S. Pat. No. 5,900,230 (May 4, 1999). It is further required that all irritants and other mouth unfriendly ingredients be absent from the dental products of this invention.
- Additional features of this invention include prevention and treatment of aphthous ulcers, oral mucositis, periodontal disease, perioral dermatitis, halitosis, oral candida, chapped lips, and oral plaque and tartar. This invention also ameliorates the condition of those who suffer from xerostomia and cold sores.
- dentinal hypersensitivity also known as tooth sensitivity.
- This malady is characterized by pain associated with ingestion of hot or cold foods, or sweets, or salty food, or pressure from toothbrushing. It is due to open dentinal tubules, usually near the gum line.
- Tooth sensitivity is mainly caused by:
- a better approach is to use a dentinal tubule occluding agent. It is known that the average diameter of dentinal tubules in humans is about 1 micrometer (1 ⁇ ). See: K. Forssell-Ahlberg et al., Acta Odon. Scand., 33, 243 (1975). In order for a particle to enter and occlude a dentinal tubule, it must have a diameter less than said tubule. Most prior art does not tabulate or graph the particle size distribution of the dentinal tubule occluding particles under consideration. Absent such information, when a particle size is mentioned, the reader should assume what is meant is average particle size.
- SQUIGLE® Enamel Saver® Toothpaste was also found to eliminate dentinal hypersensitivity in about half of all users who had this condition and used SQUIGLE® Toothpaste regularly. Since SQUIGLE® has no local anesthetics, such as potassium nitrate and/or other soluble potassium salts, its efficacy must be due to the finely divided solids present therein, such as the submicron portion of the abrasive silica and the colorant titanium dioxide, acting as dentinal tubule occluding agents, aided by the 36% xylitol and the surfactant system used in said toothpaste.
- SQUIGLE® Enamel Saver® Toothpaste was also found to eliminate dentinal hypersensitivity in about half of all users who had this condition and used SQUIGLE® Toothpaste regularly. Since SQUIGLE® has no local anesthetics, such as potassium nitrate and/or other soluble potassium salts, its efficacy must be due to the fine
- HAP toothpastes containing micro- and nanocrystals of HAP include Apagen Toothpaste (made in Italy), Apagard Toothpaste (made in Japan), and Oral-B Sensitive (made in the Netherlands).
- Table 1 provides a list of patents which describe crystalline HAP products used to treat dentinal hypersensitivity.
- crystalline hydroxyapatite One problem with crystalline hydroxyapatite is its acicular shape. Much effort has been expended in attempts to modify the natural shape of hydroxyapatite, in order to make it less needle like, and thus less toxic to mammalian cells. A similar problem exists with silica, which can exist in both the acicular and spheroidal shape. It is relatively easy to make amorphous (spheroidal) silica; however, amorphous silica is not metabolized by mammalian cells. Calcite does not have a shape problem—it is naturally cuboidal, and it is easily metabolized by mammalian cells.
- nanocalcite can be blended with thickeners, including, among others, cellulose gum and/or hydroxyethyl cellulose and/or poloxamer.
- thickeners including, among others, cellulose gum and/or hydroxyethyl cellulose and/or poloxamer.
- surfactant system of U.S. Pat. No. 5,900,230 and U.S. Pat. No. 5,496,541 is not mentioned.
- JP9-295924 does not mention the effect of submicron sized calcite on dentinal hypersensitivity.
- JP11-35438 discusses dental products containing nanocalcite plus dextranase plus anionic detergents such as sodium N-lauroyl sarcosinate and sodium lauryl sulfate.
- anionic detergents such as sodium N-lauroyl sarcosinate and sodium lauryl sulfate.
- the dental products of my invention explicitly avoid use of anionic detergents, and dextranase is not mentioned.
- nanocalcite can be blended with thickeners including, among others, cellulose gum and/or hydroxyethyl cellulose. Pluronic is mentioned, among others, as a detergent (paragraph 19). But the surfactant system of U.S. Pat. No. 5,900,230 and U.S. Pat. No. 5,496,541 is not mentioned. Xylitol is never mentioned. And the effect of nanocalcite on dentinal hypersensitivity is not mentioned.
- colloidal calcite can be blended with thickeners including, among others, cellulose gum and/or hydroxyethyl cellulose and/or poloxamer.
- thickeners including, among others, cellulose gum and/or hydroxyethyl cellulose and/or poloxamer.
- surfactant system of U.S. Pat. No. 5,900,230 and U.S. Pat. No. 5,496,541 is not mentioned.
- Xylitol is mentioned as a humectant, among others (paragraph 21), but its antiplaque properties are not mentioned.
- nanocalcite on dentinal hypersensitivity is not mentioned.
- JP2008-7479 discusses dental products to combat caries, gum disease, and halitosis.
- Said products contain slightly water soluble medicinals (paragraph 18), such as triclosan, surrounded by a nanocalcite layer, in an aqueous sugar alcohol suspending liquid.
- Xylitol and sorbitol are the preferred sugar alcohols (paragraph 60). But the antiplaque properties of xylitol are not mentioned, and simple nanocalcite particles are not discussed.
- the dental products according to JP2008-7479 may contain thickeners including, among others, cellulose gum and/or hydroxyethyl cellulose. Pluronic is mentioned, among others, as a nonionic detergent (paragraph 59). But the surfactant system of U.S. Pat. No. 5,900,230 and U.S. Pat. No. 5,496,541 is not mentioned. And the effect of nanocalcite on dentinal hypersensitivity is not mentioned.
- test dentifrice contains 0.76% NaMFP
- Nakashima et al. suggest that the remineralizing ability of said dentifrice “could be ascribed solely to the presence of nanocalcite, which releases calcium ions, and probably OH ⁇ ions”.
- U.S. Pat. No. 5,718,885 discusses cationically charged colloids to treat dentinal hypersensitivity.
- These colloids comprise metal compounds including groups II A, which includes the metal calcium.
- the preferred metals are Y, Ce, Al, and Zr (claim 4 ).
- the preferred anions are halide, oxide, hydroxide, silicate, or acetate (claim 7 ). Carbonate is never mentioned as a suitable anion.
- the only possible calcium-containing colloid would have to be calcium silicate.
- This invention comprises a set of dental products and methods to prevent and treat dentinal hypersensitivity, prevent tooth decay, and heal incipient caries by means of Mouth Friendly® dental products containing calcium carbonate, having a preferred particle size of 1 to 100 nm, and a preferred weight range of 5 to 30%.
- Said products must contain 8 to 95 weight percent of xylitol, plus the surfactant system described in U.S. Pat. No. 5,496,541 (Mar. 5, 1996) and U.S. Pat. No. 5,900,230 (May 4, 1999). It is further preferred that all irritants and other mouth unfriendly ingredients be absent from the dental products of this invention.
- Additional features of this invention include prevention and treatment of aphthous ulcers, oral mucositis, periodontal disease, perioral dermatitis, halitosis, oral candida, chapped lips, and oral plaque and tartar. This invention also ameliorates the condition of those who suffer from xerostomia and cold sores.
- This invention encompasses Mouth Friendly® oral care products (including a dentifrice powder, granules, or disintegrable tablets, toothpaste, prophylaxis paste, toothpaste for infants and toddlers, dental lozenge, dental chewing gum, mouthwash, and a dry mouth paste), and the methods of use of said products to prevent and treat dentinal hypersensitivity, prevent tooth decay, and heal incipient caries. Additional features of this invention include prevention and treatment of aphthous ulcers, oral mucositis, periodontal disease, perioral dermatitis, halitosis, oral candida, chapped lips, and oral plaque and tartar. This invention also ameliorates the condition of those who suffer from xerostomia and cold sores.
- the oral care products of this invention must contain:
- the preferred weight range is 5 to 30%, and the preferred size range is 1 to 100 nm.
- the preferred weight range is 30 to 40% for toothpaste, dry mouth paste, and mouthwash, and 50 to 90% for the dental powder, granules, tablets, lozenges, and chewing gum of this invention.
- each embodiment contains 0.01 to 10% by weight of poloxamer, or a mixture of poloxamers, plus an anionic polysaccharide (AP), or a mixture of APs, plus a nonionic cellulose ether (NCE), or a mixture of NCEs, in a ternary surfactant system having enhanced foaming power relative to poloxamers alone or to poloxamers plus APs or to poloxamers plus NCEs, wherein the weight ratio of said poloxamer to said APs is greater than 1, and the weight ratio of said AP to said NCE is greater than 1.
- AP anionic polysaccharide
- NCE nonionic cellulose ether
- Poloxamers are block copolymers of ethylene oxide and propylene oxide arranged as (EO) a (PO) b (EO) a wherein the PO content ranges from 15 to 85 mole percent, and the molecular weight ranges from 1,000 to 30,000.
- the APs are selected from the group consisting of alginic acid, gum arabic, carrageenan, carboxymethyl cellulose, karaya gum, pectin, gum tragacanth, and xanthan gum.
- High molecular weight polyacrylic acids (PAAs) linear or crosslinked, can fully or partially replace the APs of this invention. Said PAAs have a molecular weight range of 700,000 to 5 million.
- the NCEs are selected from the group consisting of alkylated celluloses and hydroxyalkylated celluloses, selected from the group consisting of methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, and hydroxypropylmethylcellulose.
- High molecular weight polyethyleneoxides (PEOs) can fully or partially replace the NCEs of this invention. Said PEOs have a molecular weight range of 100,000 to 8 million
- the dental products of this invention may also contain one or more optional ingredients:
- polyol humectants selected from the group consisting of glycerol, erythritol, sorbitol, mannitol, maltitol, and polyethylene glycol.
- a mild abrasive having a hardness less than or equal to that of tooth enamel, selected from the group consisting of calcium carbonate, dibasic calcium phosphate, tribasic calcium phosphate, calcium pyrophosphate, and hydroxyapatite d.
- a strong abrasive having a hardness greater than that of tooth enamel, selected from the group consisting of alumina, silica, titania, and fluoroapatite e. 0.1 to 10% by weight of flavor f. 1 to 5000 ppm by weight of a fluoride containing compound selected from the group consisting of sodium fluoride and sodium monofluorophosphate g. 0.1 to 10% by weight of a mono-, di-, or polydentate acid or its salts selected from the group consisting of citric acid, ethylenediaminetetraacetic acid, ascorbic acid, phosphoric acid, hydrochloric acid, and sulfuric acid to adjust and maintain the pH between 6 and 10 h.
- preservative selected from the group consisting of paraben, potassium sorbate, lactoferrin, lysozyme, and calcium propionate i. 0.1 to 1.0% by weight of antioxidant selected from the group consisting of ascorbic acid, ⁇ -tocopherol, ⁇ -carotene, coenzyme Q 10 and melatonin j. 5 to 95% by weight of water k.
- a thickener selected from the group consisting of colloidal cellulose, hydrated silica, polyethylene glycol, and polyvinylpyrrolidone
- dental products of this invention being free of irritating detergents, such as sodium lauryl sulfate, sodium N-lauroyl sarcosinate, cocamidopropyl betaine, sodium N-lauroyl glutamate, and sodium methyl cocoyl taurate.
- Said dental products being free of irritating flavors and essential oils, such as phenol, thymol, carvacrol, clove, spearmint, cinnamon, eucalyptol, and no flavors present at high intensity.
- Said dental products being free of irritating antimicrobials, such as chlorhexidine, alexidine, cetylpyridinium chloride, benzalkonium chloride, benzethonium chloride, sanguinarine, and triclosan.
- Said dental products being free of irritating tartar control agents, such as inorganic phosphate salts of group I metals, including metaphosphates, polyphosphates, and pyrophosphates.
- the dental products of this invention be free of all surfactants other than those of the surfactant system of poloxamers, ⁇ APs and/or PAAs ⁇ , and ⁇ NCEs and/or PEOs ⁇ .
- the dental products of this invention be free of foam suppressors, such as sulfonated polyacrylate oligomers, polydimethylsiloxanes, and azacycloalkane-2,2-diphosphonic acids.
- foam suppressors such as sulfonated polyacrylate oligomers, polydimethylsiloxanes, and azacycloalkane-2,2-diphosphonic acids.
- the nanocalcite of this invention adheres to the hard and soft tissues of the mouth and to plaque and tartar, instantly absorbing protons and releasing Ca ++ and HCO 3 ⁇ ions whenever and wherever acid is released, thereby providing an instantaneous means to remineralize decalcified enamel.
- Exhaled breath is rich in CO 2 (4% by volume) versus room air (0.04% by volume).
- mouth air can mildly acidify the mouth, which facilitates the slow dissolution of nanocalcite, thereby helping to continuously bathe the mouth in saliva enriched in Ca ++ , which will remineralize the mouth for as many hours as the nanocalcite coating persists in the mouth.
- the nanocalcite of this invention migrates into open dentinal tubules, and sticks there, occluding open tubules within 1 to 2 weeks when teeth are brushed with the toothpaste of this invention. And said nanocalcite inhibits the formation of tartar by sequestering phosphate ions.
- the xylitol of this invention profoundly inhibits the growth of plaque, thereby facilitating migration of the nanoparticles of this invention into open dentinal tubules.
- xylitol facilitates migration of salivary calcium and phosphate ions into the open dentinal tubules, which helps cement in place the nanoparticles of this invention.
- xylitol's profound inhibition of the growth of plaque on the hard and soft tissues of the mouth facilitates the attachment of the nanocalcite particles directly to said tissues.
- xylitol transforms oral flora into a more benign (less acidogenic) group. Since xylitol profoundly inhibits the growth of plaque, the amount of calcified plaque (tartar) is reduced, too.
- the surfactant system foam of this invention adheres xylitol and the nanoparticles of this invention to the teeth and soft tissues. Said surfactant system also prevents agglomeration of the nanoparticles, and it lubricates the nanoparticles, so as to facilitate their migration into open dentinal tubules. And said surfactant system does not irritate pulpal nerves. During manufacturing, the surfactant system of this invention and the xylitol of this invention help suspend the nanoparticles.
- the soluble calcium salt of this invention immediately replaces calcium lost to decay and food acids.
- said calcium salt can also inhibit plaque bacteria and other mouth pathogens, and help preserve the products of this invention.
- Preferred antimicrobial anions include acetate and propionate.
- the lactoferrin of this invention inhibits plaque bacteria and other mouth pathogens, and helps preserve the products of this invention. Preservative efficiency testing has shown that a mixture of lactoferrin (0.01 to 0.1% by weight) and calcium propionate (0.1 to 1.0% by weight) acts synergistically to preserve the dental products of this invention and inhibit plaque bacteria and other mouth pathogens.
- One embodiment of this invention is a dentifrice comprising the mandatory ingredients, plus one or more optional ingredients, including an abrasive, water, and a mild flavor.
- One embodiment of this invention is a low abrasivity prophylaxis paste comprising the mandatory ingredients, plus one or more optional ingredients, including an abrasive, water, and a mild flavor. Said prophylaxis paste will relieve dentinal hypersensitivity in the dental office and for weeks thereafter. And it does not splatter in use, unlike the conventional, stiff prophylaxis pastes. Another advantage is that the prophylaxis paste of this invention removes surface stain, plaque, and tartar, while leaving enamel intact.
- One embodiment of this invention is a dental chewing gum comprising the mandatory ingredients, plus a mild flavor, plus 5 to 60% by weight of a gumbase selected from the group consisting of chicle and polybutenes.
- One embodiment of this invention is a dentifrice powder comprising the mandatory ingredients, plus one or more optional ingredients, including an abrasive, and a mild flavor.
- the powder can be granulated by the usual methods.
- the granules can be blended with 0.1 to 0.5% by weight of a tablet lubricant selected from the group consisting of calcium stearate, magnesium stearate, hydrogenated vegetable oil, and beeswax.
- the granules can be compressed into a tablet which disintegrates in the mouth and can then be chewed into a paste.
- One embodiment of this invention is a toothpaste for infants and toddlers.
- Current products in this class suffer from a number of problems. Some have fluoride, which should not be swallowed. Some have silicones, and silica—inadvisable to swallow. Some have sufficient glycyrrhizin to cause hypokalemia. Most do not have xylitol—an excellent plaque suppressor. Some have large amounts of calcium phosphate and/or calcium carbonate which, when swallowed, can contribute significantly to the daily calcium dose for infants and toddlers.
- Some toothpastes for infants and toddlers have harsh detergents, such as SLS and cocamidopropyl betaine, which young children hate to taste.
- a toothpaste for infants or toddlers should be ingestible without harm, providing only a minor contribution to their daily calcium requirement.
- Such a product, according to this invention has a total calcium content of 5 to 10% by weight. Said formulation is excellent at healing or preventing caries, and it can be left in the mouth after brushing, without rinsing, to further reduce the opportunity for caries to occur.
- One embodiment of this invention is a dental lozenge which can be sucked on by the user to treat and prevent caries, periodontal disease, halitosis, tooth sensitivity, and the other maladies addressed by the products of this invention.
- One embodiment of this invention is a mouthwash which can be swished in the mouth and gargled before expectorating, to treat and prevent caries, periodontal disease, halitosis, tooth sensitivity, and the other maladies addressed by the products of this invention.
- One embodiment of this invention is a dry mouth paste which can be placed in the mouth and applied all over the mouth, and swallowed whenever the user wishes.
- Said dry mouth paste is intended to ameliorate the condition of those who suffer from dry mouth by reducing irritation, and helping to keep the mouth moist.
- the total nanocalcite content of said dry mouth paste is 5 to 10% by weight. Said paste will treat and prevent caries, periodontal disease, halitosis, tooth sensitivity, and the other maladies addressed by the products of this invention.
- a squib of this dry mouth paste can be placed in the mouth of a patient suffering from xerostomia, immediately before they go to sleep, in order to provide maximum protection against caries, gum disease, and oral candida infection while they sleep.
- a squib of this dry mouth paste can be placed in the mouth of a patient suffering from xerostomia once every 2 hours throughout the day, in order to provide maximum protection against caries, gum disease, and oral candida infection.
- One of the embodiments of this invention is a dentifrice powder or granules.
- a typical formula for a dentifrice powder or granules according to the claims of this invention is:
- the granules can be blended with 0.5% by weight of a tablet lubricant and compressed into a tablet which disintegrates in the mouth and can then be chewed into a paste.
- One of the embodiments of this invention is a dentifrice.
- a typical formula for a dentifrice according to the claims of this invention is:
- This dentifrice can also be used as a low abrasivity prophylaxis paste.
- a typical formula for an ingestible toothpaste according to the claims of this invention is:
- One of the embodiments of this invention is a dental lozenge.
- a typical formula for a lozenge according to the claims of this invention is:
- One of the embodiments of this invention is a dental chewing gum.
- a typical formula for a chewing gum according to the claims of this invention is:
- One of the embodiments of this invention is a mouthwash.
- a typical formula for a mouthwash according to the claims of this invention is:
- TOOTH BUILDER® Toothpaste is a product of SQUIGLE, inc, formulated according to the claims of this invention. It first appeared on the market in March, 2009.
- TOOTH BUILDER® Before you retire, floss, then brush your teeth with TOOTH BUILDER®. Gently brush your tongue, the roof of your mouth, and your cheeks. Rinse. Then place a new squib of TOOTH BUILDER® in your mouth and spread it around, especially on your tongue. Do not expectorate, but you may swallow. Go to sleep and, when you awake, your breath will be fresh and clean.
- a typical dry mouth paste according to the claims of this invention is:
- a squib of this dry mouth paste can be placed in the mouth of a patient suffering from xerostomia once every 2 hours throughout the day, in order to provide maximum protection against caries, gum disease, and oral candida infection.
- a squib of this dry mouth paste can be placed in the mouth of a patient suffering from xerostomia, immediately before they go to sleep, in order to provide maximum protection against caries, gum disease, and oral candida infection while they sleep.
- Aphthous ulcers canker sores, mouth ulcers
- perioral dermatitis and chapped lips are mainly due to harsh ingredients in oral care products causing irritation in people with sensitive skin in the mouth, lips, and the skin surrounding the mouth.
- Oral mucositis is a condition that occurs when cancer patients are given certain chemotherapeutic agents, which interfere with the normal growth and reproduction of the skin inside the mouth. This situation predisposes said patients to ulceration at the slightest provocation, such as the use of conventional oral care products which contain many irritating ingredients. This problem is best treated and prevented by:
- Cold sores are an oral disease caused by a herpes virus which can infect the lips, tongue, and oral mucosa. Most of the time, the virus is in its latent state, and the patient is asymptomatic. But irritation and stress can trigger a reemergence of the virus.
- One of the triggers is the use of conventional oral care products, which contain many irritating ingredients. Although they cannot currently be cured (permanently eradicated), cold sores can be reduced in frequency, and outbreaks can be ameliorated by:
- the fungus candida albicans is an indigenous inhabitant of many body orifices, including the mouth and throat. Normally, it does no harm, but if an overgrowth occurs, symptoms appear, including pain, and eventually oral cancer, if a rampant infection persists for years.
- a properly tuned immune system can keep candida in check. But irritation and stress can trigger an overgrowth, and recurrence of symptoms in susceptible individuals.
- One of the triggers is the use of conventional oral care products, which contain many irritating ingredients.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Biochemistry (AREA)
- Emergency Medicine (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Cosmetics (AREA)
Abstract
Description
-
- corrosion of enamel by acidic food and beverages
- overzealous toothbrushing
- excessively abrasive toothpastes
- use of ultra abrasive prophylaxis pastes when you get your teeth cleaned at the dentist
- gastric reflux—voluntary or involuntary
- gum recession
- bruxism
- M. Addy et al., Brit. Dent. J., 163, 45 (1987)
- M. Addy, P. Mostafa, J. Oral Rehabilitation, 16, 35 (1989)
- D. Gillam et al., J. Clin. Periodontol., 19, 197 (1992)
- D. Gillam et al., J. Periodontol., 63, 7 (1992)
- M. Kuroiwa et al., J. Periodontol., 65, 291 (1994)
- E. Absi et al., J. Oral Rehabilitation, 22, 175 (1995)
- C. Prati et al., J. Periodontol., 73, 183 (2002)
- N. West et al., J. Oral Rehabilitation, 29, 167 (2002)
TABLE 1 |
Crystalline Hydroxyapaptite (HAP) Products |
used to treat Dentinal Hypersensitivity |
Application or | Publication or | ||
Pat. No. | Issue Date | ||
U.S. Pat. No. 4,634,589 | Jan. 6, 1987 | ||
EP 346,957 | Dec. 5, 1989 | ||
U.S. Pat. No. 4,988,499 | Jan. 29, 1991 | ||
U.S. Pat. No. 5,135,396 | Aug. 4, 1992 | ||
JP 6-122,616 | May 6, 1994 | ||
JP 9-175,963 | Jul. 8, 1997 | ||
JP 9-235,215 | Sep. 9, 1997 | ||
JP 10-59,814 | Mar. 3, 1998 | ||
JP 10-109,915 | Apr. 28, 1998 | ||
U.S. Pat. No. 5,833,959 | Nov. 10, 1998 | ||
JP 10-330,234 | Dec. 15, 1998 | ||
WO 99/20237 | Apr. 29, 1999 | ||
JP 2001-213,746 | Aug. 7, 2001 | ||
Nanotoxicity—The Shape Problem
-
- a. Mixing solutions of Ca+2 and (PO4)−3
- (see U.S. Pat. No. 5,605,675 Feb. 25, 1997)
- b. Mixing finely divided sodium calcium phosphosilicate glass with saliva
- (see U.S. Pat. No. 6,338,751 Jan. 15, 2002)
- c. Coating teeth with calcium phosphopeptides
- (see U.S. Pat. No. 5,981,475 Nov. 9, 1999)
- d. Brushing with an anhydrous toothpaste containing {water soluble calcium salts} and {water soluble phosphates or silicates} (see U.S. Pat. No. 7,182,937 Feb. 27, 2007)
- a. Mixing solutions of Ca+2 and (PO4)−3
- S. Assev, G. Rölla, Caries Res., 29, 297 (1995).
- S. Assev et al., Eur. J. Oral Sci., 105, 178 (1997).
TABLE 2 |
Miscellaneous products used to Treat Dentinal Hypersensitivity |
Application or | Publication | |
Pat. No. | or Issue Date | Description |
EP 0721773 | Jul. 17, 1996 | Ca-polymer emulsions + |
oxalic acid | ||
JP 60184007 | Sep. 19, 1985 | Al chlorohydroxide-propylene |
glycol | ||
U.S. Pat. No. 4,645,662 | Feb. 24, 1987 | Al carboxylate |
U.S. Pat. No. 4,992,258 | Feb. 12, 1991 | montmorillonite clay + |
polymeric polycarboxylate | ||
U.S. Pat. No. 5,244,651 | Sep. 14, 1993 | colloidal metal polyol |
phosphates | ||
U.S. Pat. No. 5,589,159 | Dec. 31, 1996 | laponite clay |
U.S. Pat. No. 5,597,552 | Jan. 28, 1997 | polyacrylic acid salts |
U.S. Pat. No. 5,693,314 | Dec. 2, 1997 | SnF2 and KNO3 |
U.S. Pat. No. 5,718,885 | Feb. 17, 1998 | cationically charged metal |
colloids | ||
U.S. Pat. No. 5,766,011 | Jun. 16, 1998 | pH 9.5 + NaF |
U.S. Pat. No. 5,843,409 | Dec. 1, 1998 | SnF2 and KNO3 |
U.S. Pat. No. 5,874,066 | Feb. 23, 1999 | SrCl2 or CaCl2 + K oxalate |
U.S. Pat. No. 5,906,809 | May 25, 1999 | SrCl2 or CaCl2 + K oxalate |
U.S. Pat. No. 6,180,089 | Jan. 30, 2001 | NaF and KNO3 |
U.S. Pat. No. 6,241,972 | Jun. 5, 2001 | polymeric polycarboxylic |
acid salts | ||
U.S. Pat. No. 6,416,745 | Jul. 9, 2002 | anionic liposomes |
U.S. Pat. No. 6,447,756 | Sep. 10, 2002 | Na silicate + KNO3 |
U.S. Pat. No. 6,953,817 | Oct. 11, 2005 | SnF2 and KNO3 |
US 2001/0044096 | Nov. 22, 2001 | acceleration of desensitization |
by heating | ||
US 2002/0037258 | Mar. 28, 2002 | calcium silicate mixtures |
US 2002/0041852 | Apr. 11, 2002 | organic polymer tubule |
occluders | ||
US 2003/0215401 | Nov. 20, 2003 | organic polymer tubule |
occluders | ||
US 2004/0022746 | Feb. 5, 2004 | SnF2 and KNO3 |
US 2004/0022747 | Feb. 5, 2004 | SnF2 and KNO3 |
US 2004/0086467 | May 6, 2004 | coated substrates |
US 2004/0185027 | Sep. 23, 2004 | mono-and dialkylphosphate |
esters | ||
US 2007/0059257 | Mar. 15, 2007 | organic polymer tubule |
occluders | ||
US 2007/0196287 | Aug. 23, 2007 | F− plus a low concentration |
of KNO3 | ||
c. 1 to 60% by weight of a mild abrasive, having a hardness less than or equal to that of tooth enamel, selected from the group consisting of calcium carbonate, dibasic calcium phosphate, tribasic calcium phosphate, calcium pyrophosphate, and hydroxyapatite
d. 1 to 60% by weight of a strong abrasive, having a hardness greater than that of tooth enamel, selected from the group consisting of alumina, silica, titania, and fluoroapatite
e. 0.1 to 10% by weight of flavor
f. 1 to 5000 ppm by weight of a fluoride containing compound selected from the group consisting of sodium fluoride and sodium monofluorophosphate
g. 0.1 to 10% by weight of a mono-, di-, or polydentate acid or its salts selected from the group consisting of citric acid, ethylenediaminetetraacetic acid, ascorbic acid, phosphoric acid, hydrochloric acid, and sulfuric acid to adjust and maintain the pH between 6 and 10
h. 0.1 to 1.0% by weight of preservative selected from the group consisting of paraben, potassium sorbate, lactoferrin, lysozyme, and calcium propionate
i. 0.1 to 1.0% by weight of antioxidant selected from the group consisting of ascorbic acid, α-tocopherol, β-carotene, coenzyme Q10 and melatonin
j. 5 to 95% by weight of water
k. 0.1 to 10% of a thickener selected from the group consisting of colloidal cellulose, hydrated silica, polyethylene glycol, and polyvinylpyrrolidone
Ingredient | Weight % | ||
nanosized CaCO3 (Multifex MM) | 30.0 | ||
xylitol | 51.0 | ||
microcrystalline cellulose | 15.0 | ||
Pluronic F127 | 2.0 | ||
xanthan gum | 1.0 | ||
Methocel K15M | 0.5 | ||
flavor | 0.5 | ||
Ingredient | Weight % | ||
xylitol | 36.0 | ||
water | 32.0 | ||
nanosized CaCO3 (Multifex MM) | 10.0 | ||
abrasive CaCO3 (CalEssence 1500) | 5.0 | ||
glycerin | 10.1 | ||
Pluronic F127 | 4.0 | ||
cellulose gum (Aqualon 7MF) | 1.4 | ||
Methocel K15M | 0.5 | ||
flavor | 1.0 | ||
Ingredient | Weight % | ||
xylitol | 36.0 | ||
water | 30.0 | ||
nanosized CaCO3 (Multifex MM) | 5.0 | ||
glycerin | 22.1 | ||
Pluronic F127 | 4.0 | ||
cellulose gum (Aqualon 7MF) | 1.4 | ||
Methocel K15M | 0.5 | ||
flavor | 1.0 | ||
Ingredient | Weight % | ||
xylitol | 90.0 | ||
nanosized CaCO3 (Multifex MM) | 6.0 | ||
Pluronic F127 | 2.0 | ||
cellulose gum (Aqualon 7MF) | 1.0 | ||
Methocel K15M | 0.5 | ||
flavor | 0.5 | ||
Ingredient | Weight % | ||
xylitol | 70.0 | ||
gum base | 20.0 | ||
nanosized CaCO3 (Multifex MM) | 5.0 | ||
Pluronic F127 | 2.0 | ||
cellulose gum (Aqualon 7MF) | 1.0 | ||
Methocel K15M | 0.5 | ||
flavor | 1.5 | ||
Ingredient | Weight % | ||
water | 47.0 | ||
xylitol | 36.0 | ||
nanosized CaCO3 (Multifex MM) | 5.0 | ||
glycerin | 9.2 | ||
Pluronic F127 | 1.6 | ||
flavor | 0.5 | ||
preservative | 0.4 | ||
cellulose gum (Aqualon 7MF) | 0.2 | ||
Methocel K15M | 0.1 | ||
Ingredient | Weight % | ||
xylitol | 36.0 | ||
water | 32.0 | ||
nanosized CaCO3 (Multifex MM) | 10.0 | ||
glycerin | 15.1 | ||
Pluronic F127 | 4.0 | ||
cellulose gum (Aqualon 7MF) | 1.4 | ||
Methocel K15M | 0.5 | ||
flavor | 1.0 | ||
Claims (23)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/660,485 US8658139B1 (en) | 2010-02-27 | 2010-02-27 | Prevention and treatment of oral diseases |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/660,485 US8658139B1 (en) | 2010-02-27 | 2010-02-27 | Prevention and treatment of oral diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
US8658139B1 true US8658139B1 (en) | 2014-02-25 |
Family
ID=50115043
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/660,485 Active 2032-01-14 US8658139B1 (en) | 2010-02-27 | 2010-02-27 | Prevention and treatment of oral diseases |
Country Status (1)
Country | Link |
---|---|
US (1) | US8658139B1 (en) |
Cited By (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2921173A1 (en) * | 2014-03-21 | 2015-09-23 | Omya International AG | Surface-reacted calcium carbonate for desensitizing teeth |
WO2016094054A1 (en) * | 2014-12-10 | 2016-06-16 | Elevate Oral Care, Llc | Composition for the relief of dry mouth |
WO2016101158A1 (en) * | 2014-12-24 | 2016-06-30 | Colgate-Palmolive Company | Oral care composition |
JP2016222579A (en) * | 2015-05-29 | 2016-12-28 | ライオン株式会社 | Composition for oral cavity |
US9833386B2 (en) | 2006-03-30 | 2017-12-05 | James D. Welch | Method of, and system for smoothing teeth |
WO2018011192A1 (en) * | 2016-07-12 | 2018-01-18 | Centre National De La Recherche Scientifique | Compositions useful for mucosal healing |
EP3311806A1 (en) * | 2016-10-21 | 2018-04-25 | Louis Johan Wagenaar | Composition for repair of the mucous membrane |
US20180140521A1 (en) * | 2016-11-18 | 2018-05-24 | Johnson & Johnson Consumer Inc. | Method of Providing Oral Care Benefits |
WO2018093501A1 (en) * | 2016-11-18 | 2018-05-24 | Fertin Pharma A/S | Method of providing oral care benefits |
CN109480049A (en) * | 2018-12-27 | 2019-03-19 | 白昀易 | Chewing gum and preparation method thereof |
US10342646B2 (en) | 2015-10-17 | 2019-07-09 | James D. Welch | Method of, and system for smoothing teeth |
US10543205B2 (en) | 2016-11-18 | 2020-01-28 | Fertin Pharma A/S | Oral delivery vehicle containing nicotine |
US10632076B2 (en) | 2016-11-18 | 2020-04-28 | Fertin Pharma A/S | Tablet comprising separate binder and erythritol |
WO2020172424A1 (en) * | 2019-02-20 | 2020-08-27 | One Home Brands, Inc. | Stable anhydrous toothpaste concentrate formulation and method of making same |
US11052047B2 (en) | 2018-05-17 | 2021-07-06 | Fertin Pharma A/S | Oral tablet suitable for fast release of active pharmaceutical ingredients |
US11058633B2 (en) | 2018-05-17 | 2021-07-13 | Fertin Pharma A/S | Disintegrating oral tablet suitable for active pharmaceutical ingredients |
US11058641B2 (en) | 2018-05-17 | 2021-07-13 | Fertin Pharma A/S | Oral tablet for taste masking of active ingredients |
US11090263B2 (en) | 2018-05-22 | 2021-08-17 | Fertin Pharma A/S | Tableted chewing gum suitable for active pharmaceutical ingredients |
US11096895B2 (en) | 2018-05-17 | 2021-08-24 | Fertin Pharma A/S | Oral tablet suitable for active pharmaceutical ingredients |
US11096894B2 (en) | 2018-05-17 | 2021-08-24 | Fertin Pharma A/S | Oral tablet for induced saliva generation |
US11096896B2 (en) | 2018-05-17 | 2021-08-24 | Fertin Pharma A/S | Tablet dosage form for buccal absorption of active ingredients |
US11135157B2 (en) | 2018-05-17 | 2021-10-05 | Fertin Pharma A/S | Oral tablet for delivery of active ingredients to the throat |
US11260030B2 (en) | 2018-05-17 | 2022-03-01 | Fertin Pharma A/S | Oral tablet for delivery of active ingredients to the gastrointestinal tract |
US20220110838A1 (en) * | 2020-08-28 | 2022-04-14 | Evoq Nano, Inc. | Oral care nanoparticle compositions and methods |
CN114751389A (en) * | 2022-04-27 | 2022-07-15 | 广东省地质实验测试中心 | Selenium-based modified nano hydroxyapatite material, preparation method thereof and application thereof in Cd-contaminated soil remediation |
WO2022200887A1 (en) * | 2021-03-25 | 2022-09-29 | Kwok Wannarat | Natural multifunction coenzyme q10 liquid oral hygiene care with antimicrobial efficacy |
US20220339082A1 (en) * | 2021-04-23 | 2022-10-27 | Colgate-Palmolive Company | Solid Oral Care Compositions |
RU2783120C2 (en) * | 2016-11-18 | 2022-11-09 | Фертин Фарма А/С | Method for provision of therapeutic and preventive effects of oral care |
US12083209B2 (en) | 2020-02-18 | 2024-09-10 | Sunstar Americas, Inc. | Oral care composition |
WO2025111132A3 (en) * | 2023-11-22 | 2025-07-03 | Biom, Llc | Toothpaste tablet having xylitol and nano-hydroxyapatite |
Citations (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60184007A (en) | 1984-03-03 | 1985-09-19 | Lion Corp | Composition for oral cavity application |
US4634589A (en) | 1984-05-18 | 1987-01-06 | Wurttembergische Parfumerie-Fabrik Gmbh | Dentifrice for hypersensitive teeth |
US4645662A (en) | 1984-07-26 | 1987-02-24 | Lion Corporation | Oral composition |
EP0346957A1 (en) | 1988-05-19 | 1989-12-20 | Unilever N.V. | Oral compositions |
US4988499A (en) | 1988-05-19 | 1991-01-29 | Unilever Patent Holdings, B.V. | Oral compositions |
US4992258A (en) | 1989-10-23 | 1991-02-12 | Colgate-Palmolive Company | Dentrifice composition |
US5135396A (en) | 1987-06-30 | 1992-08-04 | Kabushiki Kaisha Sangi | Fine filling method and fine filler for dental purposes |
US5244651A (en) | 1991-09-04 | 1993-09-14 | Kao Corporation | Method of desensitizing hypersensitive dentin |
JPH06122616A (en) | 1992-10-12 | 1994-05-06 | Sangi Co Ltd | White toothpaste composition |
US5496541A (en) * | 1993-01-19 | 1996-03-05 | Pilot Research & Development Co. | Tasteful toothpaste and other dental products |
EP0721773A2 (en) | 1994-12-13 | 1996-07-17 | Sun Medical Co., Ltd. | Dental composition for relieving dentin hypersensitivity |
US5589159A (en) | 1995-04-11 | 1996-12-31 | Block Drug Company Inc. | Dispersible particulate system for desensitizing teeth |
US5597552A (en) | 1991-12-20 | 1997-01-28 | Block Drug Company Inc. | Dentinal desensitizing compositions |
US5605675A (en) | 1995-06-06 | 1997-02-25 | Enamelon Inc. | Processes and compositions for remineralization and prevention of demineralization of dental enamel |
US5624906A (en) * | 1994-12-08 | 1997-04-29 | Lever Brothers Company, Division Of Conopco, Inc. | Oral hygiene compositions comprising heteroatom containing alkyl aldonamide compounds |
JPH09175963A (en) | 1995-12-26 | 1997-07-08 | Sangi Co Ltd | Toothpaste composition |
JPH09235215A (en) | 1996-02-29 | 1997-09-09 | Lion Corp | Oral composition |
JPH09295924A (en) | 1996-04-30 | 1997-11-18 | Lion Corp | Dental plaque acid neutralizer and oral composition |
US5693314A (en) | 1994-08-08 | 1997-12-02 | Colgate Palmolive Company | Two component dentifrice for the treatment of dentinal hypersensitivity |
US5718885A (en) | 1994-06-06 | 1998-02-17 | Block Drug Co., Inc. | Relief of dentinal hypersensitivity by submicron particles |
JPH1059814A (en) | 1996-08-13 | 1998-03-03 | Kanebo Ltd | Composition for oral cavity |
JPH10109915A (en) | 1996-10-04 | 1998-04-28 | Kanebo Ltd | Composition for oral cavity |
US5762911A (en) | 1996-03-05 | 1998-06-09 | The Research Foundation Of State University Of New York | Anti-caries oral compositions |
US5766011A (en) | 1996-11-27 | 1998-06-16 | Sibner; Jeffrey A. | Dental bleaching composition and method |
US5833959A (en) | 1996-01-24 | 1998-11-10 | Sangi Co., Ltd. | Compositions for dental tissue |
JPH10330234A (en) | 1997-05-30 | 1998-12-15 | Shosuke Otsuka | Dentifrice |
JPH1135438A (en) | 1997-07-17 | 1999-02-09 | Lion Corp | Oral composition |
US5874066A (en) | 1994-08-01 | 1999-02-23 | University Of Maryland, Baltimore | Method and kit for treating tooth hypersensitivity |
WO1999020237A1 (en) | 1997-10-17 | 1999-04-29 | Zakrytoe Aktsionernoe Obschestvo Ostim | Stomatic composition |
US5900230A (en) | 1997-08-18 | 1999-05-04 | Squigle, Inc. | Dental products to treat and prevent periodontal disease |
JPH11130643A (en) | 1997-10-28 | 1999-05-18 | Lion Corp | Oral composition |
US5906809A (en) | 1995-10-19 | 1999-05-25 | University Of Maryland, Baltimore | One-step method and preparation for reducing dentinal hypersensitivity |
US5981475A (en) | 1992-06-29 | 1999-11-09 | The University Of Melbourne | Treatment for sensitive teeth |
US6180089B1 (en) | 1999-01-21 | 2001-01-30 | Colgate-Palmolive Company | Dual component dentinal desensitizing dentifrice |
US6241972B1 (en) | 1999-02-19 | 2001-06-05 | Block Drug Company, Inc. | Oral care formulation for the treatment of sensitivity teeth |
JP2001213746A (en) | 2000-02-01 | 2001-08-07 | Sangi Co Ltd | Composition for mouth |
US20010044096A1 (en) | 2000-05-08 | 2001-11-22 | Lindquist Sherrill F. | Methods for accelerated desensitization of teeth |
US6338751B1 (en) | 1996-02-07 | 2002-01-15 | Usbiomaterials Corp | Compositions containing bioactive glass and their use in treating tooth hypersensitivity |
US20020037258A1 (en) | 1999-08-05 | 2002-03-28 | Gregory P. Dodd | Dental composition for the mineral occlusion of dentinal tubules in sensitive teeth |
US20020041852A1 (en) | 2000-08-18 | 2002-04-11 | Napolitano Neil J. | Dental composition for hypersensitive teeth |
CN1348757A (en) | 2001-10-30 | 2002-05-15 | 张雷 | Caries preventing nano tooth paste |
US6416745B1 (en) | 2001-05-03 | 2002-07-09 | Block Drug Company, Inc. | Dental composition for treating hypersensitive teeth |
US6436370B1 (en) | 1999-06-23 | 2002-08-20 | The Research Foundation Of State University Of New York | Dental anti-hypersensitivity composition and method |
US6447756B1 (en) | 2000-11-08 | 2002-09-10 | Colgate Palmolive Company | Desensitizing dual component dentifrice |
US20030215401A1 (en) | 2000-08-21 | 2003-11-20 | David Estrada | Dental composition for hypersensitve teeth |
US20040022747A1 (en) | 2002-08-05 | 2004-02-05 | Colgate-Palmolive Company | Dentinal desensitizing dentifrice providing enhanced remineralization and anticaries benefits |
US20040086467A1 (en) | 2001-10-10 | 2004-05-06 | Frederick Curro | Dental compositions for hypersensitive teeth |
US20040185027A1 (en) | 2003-02-21 | 2004-09-23 | Reierson Robert Lee | Anti-sensitivity, anti-caries, anti-staining, anti-plaque, ultra-mild oral hygiene agent |
US20060193792A1 (en) * | 2002-10-04 | 2006-08-31 | The Procter & Gamble Company | Use of an oral composition |
US7182937B2 (en) | 2000-10-13 | 2007-02-27 | Block Drug Company, Inc. | Anhydrous dentrifice formulations for the delivery of incompatible ingredients |
US20070059257A1 (en) | 2000-08-18 | 2007-03-15 | Block Drug Company, Inc. | Dentinal composition for hypersensitive teeth |
US20070196287A1 (en) | 1998-11-12 | 2007-08-23 | Ultradent Products, Inc. | Methods for bleaching and desensitizing teeth |
JP2008007479A (en) | 2006-06-30 | 2008-01-17 | Lion Corp | Composition for oral cavity and method for producing aqueous dispersion of sugar alcohol aqueous solution of calcium carbonate-coated poorly water-soluble medicinal component fine particles |
-
2010
- 2010-02-27 US US12/660,485 patent/US8658139B1/en active Active
Patent Citations (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60184007A (en) | 1984-03-03 | 1985-09-19 | Lion Corp | Composition for oral cavity application |
US4634589A (en) | 1984-05-18 | 1987-01-06 | Wurttembergische Parfumerie-Fabrik Gmbh | Dentifrice for hypersensitive teeth |
US4645662A (en) | 1984-07-26 | 1987-02-24 | Lion Corporation | Oral composition |
US5135396A (en) | 1987-06-30 | 1992-08-04 | Kabushiki Kaisha Sangi | Fine filling method and fine filler for dental purposes |
EP0346957A1 (en) | 1988-05-19 | 1989-12-20 | Unilever N.V. | Oral compositions |
US4988499A (en) | 1988-05-19 | 1991-01-29 | Unilever Patent Holdings, B.V. | Oral compositions |
US4992258A (en) | 1989-10-23 | 1991-02-12 | Colgate-Palmolive Company | Dentrifice composition |
US5244651A (en) | 1991-09-04 | 1993-09-14 | Kao Corporation | Method of desensitizing hypersensitive dentin |
US5597552A (en) | 1991-12-20 | 1997-01-28 | Block Drug Company Inc. | Dentinal desensitizing compositions |
US5981475A (en) | 1992-06-29 | 1999-11-09 | The University Of Melbourne | Treatment for sensitive teeth |
JPH06122616A (en) | 1992-10-12 | 1994-05-06 | Sangi Co Ltd | White toothpaste composition |
US5496541A (en) * | 1993-01-19 | 1996-03-05 | Pilot Research & Development Co. | Tasteful toothpaste and other dental products |
US5496541C1 (en) * | 1993-01-19 | 2001-06-26 | Squigle Inc | Tasteful toothpaste and other dental products |
US5718885A (en) | 1994-06-06 | 1998-02-17 | Block Drug Co., Inc. | Relief of dentinal hypersensitivity by submicron particles |
US5874066A (en) | 1994-08-01 | 1999-02-23 | University Of Maryland, Baltimore | Method and kit for treating tooth hypersensitivity |
US5843409A (en) | 1994-08-08 | 1998-12-01 | Colgate Palmolive Company | Two component dentifrice for the treatment of dentinal hypersensitivity |
US5693314A (en) | 1994-08-08 | 1997-12-02 | Colgate Palmolive Company | Two component dentifrice for the treatment of dentinal hypersensitivity |
US5624906A (en) * | 1994-12-08 | 1997-04-29 | Lever Brothers Company, Division Of Conopco, Inc. | Oral hygiene compositions comprising heteroatom containing alkyl aldonamide compounds |
EP0721773A2 (en) | 1994-12-13 | 1996-07-17 | Sun Medical Co., Ltd. | Dental composition for relieving dentin hypersensitivity |
US5589159A (en) | 1995-04-11 | 1996-12-31 | Block Drug Company Inc. | Dispersible particulate system for desensitizing teeth |
US5605675A (en) | 1995-06-06 | 1997-02-25 | Enamelon Inc. | Processes and compositions for remineralization and prevention of demineralization of dental enamel |
US5906809A (en) | 1995-10-19 | 1999-05-25 | University Of Maryland, Baltimore | One-step method and preparation for reducing dentinal hypersensitivity |
JPH09175963A (en) | 1995-12-26 | 1997-07-08 | Sangi Co Ltd | Toothpaste composition |
US5833959A (en) | 1996-01-24 | 1998-11-10 | Sangi Co., Ltd. | Compositions for dental tissue |
US6338751B1 (en) | 1996-02-07 | 2002-01-15 | Usbiomaterials Corp | Compositions containing bioactive glass and their use in treating tooth hypersensitivity |
JPH09235215A (en) | 1996-02-29 | 1997-09-09 | Lion Corp | Oral composition |
US5762911A (en) | 1996-03-05 | 1998-06-09 | The Research Foundation Of State University Of New York | Anti-caries oral compositions |
JPH09295924A (en) | 1996-04-30 | 1997-11-18 | Lion Corp | Dental plaque acid neutralizer and oral composition |
JPH1059814A (en) | 1996-08-13 | 1998-03-03 | Kanebo Ltd | Composition for oral cavity |
JPH10109915A (en) | 1996-10-04 | 1998-04-28 | Kanebo Ltd | Composition for oral cavity |
US5766011A (en) | 1996-11-27 | 1998-06-16 | Sibner; Jeffrey A. | Dental bleaching composition and method |
JPH10330234A (en) | 1997-05-30 | 1998-12-15 | Shosuke Otsuka | Dentifrice |
JPH1135438A (en) | 1997-07-17 | 1999-02-09 | Lion Corp | Oral composition |
US5900230A (en) | 1997-08-18 | 1999-05-04 | Squigle, Inc. | Dental products to treat and prevent periodontal disease |
WO1999020237A1 (en) | 1997-10-17 | 1999-04-29 | Zakrytoe Aktsionernoe Obschestvo Ostim | Stomatic composition |
JPH11130643A (en) | 1997-10-28 | 1999-05-18 | Lion Corp | Oral composition |
US20070196287A1 (en) | 1998-11-12 | 2007-08-23 | Ultradent Products, Inc. | Methods for bleaching and desensitizing teeth |
US6180089B1 (en) | 1999-01-21 | 2001-01-30 | Colgate-Palmolive Company | Dual component dentinal desensitizing dentifrice |
US6241972B1 (en) | 1999-02-19 | 2001-06-05 | Block Drug Company, Inc. | Oral care formulation for the treatment of sensitivity teeth |
US6436370B1 (en) | 1999-06-23 | 2002-08-20 | The Research Foundation Of State University Of New York | Dental anti-hypersensitivity composition and method |
US20030133885A1 (en) | 1999-06-23 | 2003-07-17 | The Reseaarch Foundation Of The State University Of New York | Dental anti-hypersensitivity composition and method |
US6524558B2 (en) | 1999-06-23 | 2003-02-25 | The Research Foundation Of The State University Of New York | Dental anti-hypersensitivity composition and method |
US20020037258A1 (en) | 1999-08-05 | 2002-03-28 | Gregory P. Dodd | Dental composition for the mineral occlusion of dentinal tubules in sensitive teeth |
JP2001213746A (en) | 2000-02-01 | 2001-08-07 | Sangi Co Ltd | Composition for mouth |
US20010044096A1 (en) | 2000-05-08 | 2001-11-22 | Lindquist Sherrill F. | Methods for accelerated desensitization of teeth |
US20070059257A1 (en) | 2000-08-18 | 2007-03-15 | Block Drug Company, Inc. | Dentinal composition for hypersensitive teeth |
US20020041852A1 (en) | 2000-08-18 | 2002-04-11 | Napolitano Neil J. | Dental composition for hypersensitive teeth |
US20030215401A1 (en) | 2000-08-21 | 2003-11-20 | David Estrada | Dental composition for hypersensitve teeth |
US7182937B2 (en) | 2000-10-13 | 2007-02-27 | Block Drug Company, Inc. | Anhydrous dentrifice formulations for the delivery of incompatible ingredients |
US6447756B1 (en) | 2000-11-08 | 2002-09-10 | Colgate Palmolive Company | Desensitizing dual component dentifrice |
US6416745B1 (en) | 2001-05-03 | 2002-07-09 | Block Drug Company, Inc. | Dental composition for treating hypersensitive teeth |
US20040086467A1 (en) | 2001-10-10 | 2004-05-06 | Frederick Curro | Dental compositions for hypersensitive teeth |
CN1348757A (en) | 2001-10-30 | 2002-05-15 | 张雷 | Caries preventing nano tooth paste |
US20040022746A1 (en) | 2002-08-05 | 2004-02-05 | Fisher Steven W. | Dual component dentinal desensitizing dentifrice |
US6953817B2 (en) | 2002-08-05 | 2005-10-11 | Colgate-Palmolive Company | Dual component dentinal desensitizing dentifrice |
US20040022747A1 (en) | 2002-08-05 | 2004-02-05 | Colgate-Palmolive Company | Dentinal desensitizing dentifrice providing enhanced remineralization and anticaries benefits |
US20060193792A1 (en) * | 2002-10-04 | 2006-08-31 | The Procter & Gamble Company | Use of an oral composition |
US20040185027A1 (en) | 2003-02-21 | 2004-09-23 | Reierson Robert Lee | Anti-sensitivity, anti-caries, anti-staining, anti-plaque, ultra-mild oral hygiene agent |
JP2008007479A (en) | 2006-06-30 | 2008-01-17 | Lion Corp | Composition for oral cavity and method for producing aqueous dispersion of sugar alcohol aqueous solution of calcium carbonate-coated poorly water-soluble medicinal component fine particles |
Non-Patent Citations (19)
Title |
---|
Absi et al, Dentine Hypersensitivity: uptake of toothpastes onto dentine and effects of brushing, washing and dietary acid-SEM in vitro study, J. Oral Rehabilitation, Mar. 1995, 22, 175. |
Addy et al., "Dentine hypersensitivity: a comparison of five toothpastes used during a 6-week treatment period", Brit. Dent. J., Jul. 1987,163, 45-51. |
Addy, P. Mostafa, "Dentine hypersensitivity. II. Effects produced by the uptake in vitro of toothpastes onto dentine", J. Oral Rehabilitation, Jan. 1989, 16(1), 35-48. |
Arrais, et al., "Occluding effect of dentifrices on dentinal tubules", Journal of Dentistry, Nov. 2003, 31(8), 577-584. |
Assev et al., Are sodium lauryl sulfate-Containing toothpastes suitable vehicles for xylitol? European Journal of Oral Sciences, Apr. 1997, 105(2), 178-182. |
Assev, S. and G. Rölla, Lack of xylitol uptake by bacteria in the presence of SLS, Caries Res., 1995, 29, 297. |
Barone, M. and M. Malpissi, "Clinical Trial of a 15% supermicronized hydroxyapatite gel for dentin hypersensitivity, Giornale Italiano di Endodonzia", 1991, 5 (2), 43-47. |
Cutler et al, "Gum Disease Clinical Study 1999-2000", The Effect of toothpaste on bleeding index, 2000, 1-3. |
Forssell-Ahlberg, "The diameter and number of dentinal tubules in rat, cat, dog and monkey", Acta Odon. Scand., 1975, 33(5), 243-250. |
Gillam et al., "Clinical efficacy of a low abrasive dentifrice for the relief of cervical dentinal hypersensitivity", J. Clin. Periodontol., Mar. 1992, 19(3), 197-201. |
Gillam et al., "Dentifrice abrasivity and cervical dentinal hypersensitivity. Results 12 weeks following cessation of 8 weeks' supervised use", Jan. 1992, J. Periodontol., 63(1), 7. |
Hüttemann et al. Investigation of utility and mechanics of use of hydroxyapatite for therapy of hypersensitive tooth root, ZWR, Mar. 1989, 98 (3), 240-245. |
Hüttemann, R. and H. Donges, "Treatment of dentine hypersensitivity with hydroxylapatite", Dtsch. Zahnärztl. Z., May 1987, 42(5), 486-488. |
Kuroiwa et al., Dentin hypersensitivity. Occlusion of dentinal tubules by brushing with and without an abrasive dentifrice, J. Periodontol., Apr. 1994, 65, 291-296. |
Medline Plus, Dental Caries, pp. 1-3, May 2001. * |
Melsen, B., and G. Rölla, "Reduced clinical effect of monofluorophosphate in the presence of sodium lauryl sulphate", Caries Res., 1983, 17(6), 549-553. |
Nakashima et al, "Effect of a Test Dentifrice Containing Nano-sized Calcium Carbonate on Remineralization of Enamel Lesions in Vitro", Mar. 2009, Journal of Oral Science, 51(1), 69-77. |
Prati et al., "Dentin morphology and permeability after brushing with different toothpastes in the presence and absence of smear layer", J. Periodontol., Feb. 2002, 73(2), 183-190. |
West et al., "Dentine hypersensitivity: the effects of brushing toothpaste on etched and unetched dentine in vitro", Feb. 2002, J. Oral Rehabilitation, 29(2), 167-174. |
Cited By (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9833386B2 (en) | 2006-03-30 | 2017-12-05 | James D. Welch | Method of, and system for smoothing teeth |
EP2921173A1 (en) * | 2014-03-21 | 2015-09-23 | Omya International AG | Surface-reacted calcium carbonate for desensitizing teeth |
CN106132421B (en) * | 2014-03-21 | 2021-01-29 | 欧米亚国际集团 | Surface-reacted calcium carbonate for tooth desensitization |
US10463693B2 (en) | 2014-03-21 | 2019-11-05 | Omya International Ag | Surface-reacted calcium carbonate for desensitizing teeth |
CN106132421A (en) * | 2014-03-21 | 2016-11-16 | 欧米亚国际集团 | The calcium carbonate through surface reaction for desensitizing dental |
RU2674030C2 (en) * | 2014-03-21 | 2018-12-04 | Омиа Интернэшнл Аг | Surface-reacted calcium carbonate for desensitizing teeth |
AU2015233384B2 (en) * | 2014-03-21 | 2017-08-03 | Omya International Ag | Surface-reacted calcium carbonate for desensitizing teeth |
WO2015140308A1 (en) * | 2014-03-21 | 2015-09-24 | Omya International Ag | Surface-reacted calcium carbonate for desensitizing teeth |
TWI615154B (en) * | 2014-03-21 | 2018-02-21 | 歐米亞國際公司 | Surface-reacted calcium carbonate for desensitizing teeth |
WO2016094054A1 (en) * | 2014-12-10 | 2016-06-16 | Elevate Oral Care, Llc | Composition for the relief of dry mouth |
US10772908B2 (en) | 2014-12-10 | 2020-09-15 | Elevate Oral Care, Llc | Composition for the relief of dry mouth |
AU2015361122B2 (en) * | 2014-12-10 | 2020-12-17 | Elevate Oral Care, Llc | Composition for the relief of dry mouth |
WO2016101158A1 (en) * | 2014-12-24 | 2016-06-30 | Colgate-Palmolive Company | Oral care composition |
JP2016222579A (en) * | 2015-05-29 | 2016-12-28 | ライオン株式会社 | Composition for oral cavity |
US10342646B2 (en) | 2015-10-17 | 2019-07-09 | James D. Welch | Method of, and system for smoothing teeth |
WO2018011192A1 (en) * | 2016-07-12 | 2018-01-18 | Centre National De La Recherche Scientifique | Compositions useful for mucosal healing |
US11389470B2 (en) | 2016-07-12 | 2022-07-19 | Centre National De La Recherche Scientifique | Compositions useful for mucosal healing |
EP3311806A1 (en) * | 2016-10-21 | 2018-04-25 | Louis Johan Wagenaar | Composition for repair of the mucous membrane |
WO2018093501A1 (en) * | 2016-11-18 | 2018-05-24 | Fertin Pharma A/S | Method of providing oral care benefits |
US10632076B2 (en) | 2016-11-18 | 2020-04-28 | Fertin Pharma A/S | Tablet comprising separate binder and erythritol |
US11484503B2 (en) | 2016-11-18 | 2022-11-01 | Fertin Pharma A/S | Tablet comprising separate binder and erythritol |
US10543205B2 (en) | 2016-11-18 | 2020-01-28 | Fertin Pharma A/S | Oral delivery vehicle containing nicotine |
KR20190086512A (en) * | 2016-11-18 | 2019-07-22 | 페르틴 파르마 에이/에스 | How to Provide Oral Care Effect |
RU2783120C2 (en) * | 2016-11-18 | 2022-11-09 | Фертин Фарма А/С | Method for provision of therapeutic and preventive effects of oral care |
US11351162B2 (en) | 2016-11-18 | 2022-06-07 | Fertin Pharma A/S | Oral delivery vehicle containing flavoring agents |
US20180140521A1 (en) * | 2016-11-18 | 2018-05-24 | Johnson & Johnson Consumer Inc. | Method of Providing Oral Care Benefits |
US11351103B2 (en) * | 2016-11-18 | 2022-06-07 | Johnson & Johnson Consumer Inc. | Method of providing oral care benefits |
US11052047B2 (en) | 2018-05-17 | 2021-07-06 | Fertin Pharma A/S | Oral tablet suitable for fast release of active pharmaceutical ingredients |
US11058633B2 (en) | 2018-05-17 | 2021-07-13 | Fertin Pharma A/S | Disintegrating oral tablet suitable for active pharmaceutical ingredients |
US11096894B2 (en) | 2018-05-17 | 2021-08-24 | Fertin Pharma A/S | Oral tablet for induced saliva generation |
US11096896B2 (en) | 2018-05-17 | 2021-08-24 | Fertin Pharma A/S | Tablet dosage form for buccal absorption of active ingredients |
US11135157B2 (en) | 2018-05-17 | 2021-10-05 | Fertin Pharma A/S | Oral tablet for delivery of active ingredients to the throat |
US11260030B2 (en) | 2018-05-17 | 2022-03-01 | Fertin Pharma A/S | Oral tablet for delivery of active ingredients to the gastrointestinal tract |
US11096895B2 (en) | 2018-05-17 | 2021-08-24 | Fertin Pharma A/S | Oral tablet suitable for active pharmaceutical ingredients |
US12102714B2 (en) | 2018-05-17 | 2024-10-01 | Fertin Pharma A/S | Disintegrating oral tablet suitable for active pharmaceutical ingredients |
US11058641B2 (en) | 2018-05-17 | 2021-07-13 | Fertin Pharma A/S | Oral tablet for taste masking of active ingredients |
US12156943B2 (en) | 2018-05-17 | 2024-12-03 | Fertin Pharma A/S | Tablet dosage form for buccal absorption of active ingredients |
US12109312B2 (en) | 2018-05-17 | 2024-10-08 | Fertin Pharma A/S | Oral tablet for taste masking of active ingredients |
US11090263B2 (en) | 2018-05-22 | 2021-08-17 | Fertin Pharma A/S | Tableted chewing gum suitable for active pharmaceutical ingredients |
CN109480049A (en) * | 2018-12-27 | 2019-03-19 | 白昀易 | Chewing gum and preparation method thereof |
WO2020172424A1 (en) * | 2019-02-20 | 2020-08-27 | One Home Brands, Inc. | Stable anhydrous toothpaste concentrate formulation and method of making same |
US12083209B2 (en) | 2020-02-18 | 2024-09-10 | Sunstar Americas, Inc. | Oral care composition |
US20220110838A1 (en) * | 2020-08-28 | 2022-04-14 | Evoq Nano, Inc. | Oral care nanoparticle compositions and methods |
WO2022200887A1 (en) * | 2021-03-25 | 2022-09-29 | Kwok Wannarat | Natural multifunction coenzyme q10 liquid oral hygiene care with antimicrobial efficacy |
US20220339082A1 (en) * | 2021-04-23 | 2022-10-27 | Colgate-Palmolive Company | Solid Oral Care Compositions |
CN114751389B (en) * | 2022-04-27 | 2023-10-03 | 广东省地质实验测试中心 | Selenium-based modified nano hydroxyapatite material, preparation method thereof and application thereof in restoring Cd-polluted soil |
CN114751389A (en) * | 2022-04-27 | 2022-07-15 | 广东省地质实验测试中心 | Selenium-based modified nano hydroxyapatite material, preparation method thereof and application thereof in Cd-contaminated soil remediation |
WO2025111132A3 (en) * | 2023-11-22 | 2025-07-03 | Biom, Llc | Toothpaste tablet having xylitol and nano-hydroxyapatite |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8658139B1 (en) | Prevention and treatment of oral diseases | |
US5900230A (en) | Dental products to treat and prevent periodontal disease | |
RU2452465C2 (en) | Dental compositions for xerostomia | |
JP4111916B2 (en) | Composition for alleviating xerostomia and treating related diseases | |
EP2648679B1 (en) | Dentifrice compositions containing calcium silicate and a basic amino acid | |
US5817294A (en) | Plaque adsorbent oral composition and method | |
EP2648677B1 (en) | Dentifrice compositions containing calcium silicate | |
AU2009346357B2 (en) | Oral compositions containing polyguanidinium compounds and methods of manufacture and use thereof | |
RU2587054C1 (en) | Oral care composition | |
TWI686208B (en) | Oral care compositions and methods | |
RU2455001C2 (en) | Compositions and methods of treating xerostomia | |
KR20150132404A (en) | Polyphenol/flavonoid compositions and methods of formulating oral hygienic products | |
EP2131806B1 (en) | Dental care composition comprising particulate zinc oxide | |
JP2006509767A (en) | Chewable solid unit dosage forms and methods of delivering active agents to the occlusal surface of teeth | |
IE850984L (en) | Oral hygiene compositions | |
JPH02286613A (en) | New composition | |
RU2604667C2 (en) | Oral care compositions | |
WO2025068966A4 (en) | Synergistic dentifrice (oral) composition, formulation and preparation method and application thereof | |
Maden et al. | The Efficacy of Xylitol, Xylitol-Probiotic and Fluoride Dentifrices in Plaque Reduction and Gingival Inflammation in Children: A Randomised Controlled Clinical Trial. | |
PL202563B1 (en) | Improved low−cost dentifrice composition | |
TWI688409B (en) | Oral care compositions and methods | |
JP5512791B2 (en) | Desensitizing dentifrice showing antibacterial uptake of dental tissue | |
EP2512437B1 (en) | Compositions comprising alginates with high guluronic acid/mannuronic acid ratio for use in the treatment of dentine hypersensitivity. | |
Pawar et al. | DYNAMIC FORMULATION OF EFFERVESCENT ANTIMICROBIAL MOUTHWASH REVIEW. | |
EP4420737A1 (en) | Oral care composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: SQUIGLE, INC., PENNSYLVANIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CUTLER, EDWARD T.;REEL/FRAME:031903/0773 Effective date: 20131226 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
FEPP | Fee payment procedure |
Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.) |
|
FEPP | Fee payment procedure |
Free format text: SURCHARGE FOR LATE PAYMENT, SMALL ENTITY (ORIGINAL EVENT CODE: M2554) |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2551) Year of fee payment: 4 |
|
FEPP | Fee payment procedure |
Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
FEPP | Fee payment procedure |
Free format text: 7.5 YR SURCHARGE - LATE PMT W/IN 6 MO, SMALL ENTITY (ORIGINAL EVENT CODE: M2555); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2552); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY Year of fee payment: 8 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 12TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2553); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY Year of fee payment: 12 |